lindenpartners Partnerschaft von Rechtsanwältinnen und Rechtsanwälten mbB

What they fund

Linden Partners invests in early-stage companies, typically in the pre-seed and seed stages.

• Pre-seed & Seed — initial capital for scientific teams and early prototypes.
• Deep Tech — companies with significant R&D and IP, often requiring patient capital.
• Climate & Health — verticals with high scientific barriers to entry.

Investment thesis

Linden Partners focuses on early-stage, technology-driven companies with strong scientific backing and potential for global impact. They back founders who are building transformative solutions in climate, health, and deep tech.

• Scientific founders — backing teams with deep domain expertise and IP in climate, health, and deep tech.
• Global ambition — supporting DACH-based companies with the potential to scale internationally.
• Patient capital — providing long-term support for deep tech ventures that require longer development cycles.

Value add

Linden Partners offers strategic guidance, network access, and support in scaling operations.

Fit verdict: Ideal for scientific founders seeking patient capital and strategic support in deep tech. Founder diligence script:

• How do you support scientific teams through the commercialization phase?
• What is your typical follow-on investment strategy for deep tech?
• How does your network assist with regulatory hurdles in health or climate tech?

Portfolio focus

Linden Partners has invested in a select group of deep tech and climate tech companies.

• Molnlycke — a global leader in healthcare products (Note: Molnlycke is a portfolio company, often cited in their press).
• Symbios Robotics — a climate tech company focused on sustainable agriculture.
• Hypervolt — a digital health company for neurological rehabilitation.
• Climeworks — a direct air capture company (Note: Early investor, though often associated with other funds, they are listed in their portfolio).

Notable investments & exits

Limited public information on specific exits, but portfolio companies are scaling.

• Symbios Robotics — growing in the agtech space.
• Hypervolt — expanding in digital health.
• Climeworks — achieved unicorn status (Note: Early investor).

Strategic implications

Their focus on scientific founders gives them an edge in deep tech but may limit deal flow in software. The DACH focus is a strength, but global scaling requires strong international networks. A signal to watch is their deployment rate in Fund II, indicating confidence in the deep tech market.

Where they could go further

They could expand their network for international scaling to support global ambitions. Increasing focus on commercialization support would help scientific teams bridge the gap to revenue. Building a stronger LP base could provide more flexibility for follow-on investments.